Original Publication Date: >26 May, 2016
Publication / Source: CNS Oncology
Authors: Tiffany R Hodges, Sherise D Ferguson & Amy B Heimberger
Immunotherapy for glioblastoma (GBM) provides a unique opportunity for targeted therapies for each patient, addressing individual variability in genes, tumor biomarkers and clinical profile. As immunotherapy has the potential to specifically target tumor cells with minimal risk to normal tissue, several immunotherapeutic strategies are currently being evaluated in clinical trials in GBM.